James Primer on Prostate Cancer

1. Auflage 2014
ISBN: 978-1-907673-82-5
Verlag: Springer Healthcare
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 50 Seiten, Web PDF

Reihe: Medicine (R0)

Primer on Prostate Cancer will provide readers with a thorough introductory review on prostate cancer, treatment guidelines, and emerging therapies available for the disease. The book was originally commissioned due to recent developments in therapies for prostate cancer. This concise pocket book will review prostate cancer’s epidemiology, clinical features, diagnosis, and medical management (discussing surgery, radiotherapy, hormone therapy, chemotherapy, bone-targeting therapy, and more). Busy healthcare professionals will benefit from this text, which will not only cover the basics of prostate cancer, but discuss up-to-date national and international treatment guidelines and upcoming therapies.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

James, Nicholas

Inhaltsverzeichnis

Author biography.- Abbreviation.- Preface.- Epidemiology of prostate cancer.- Clinical features and diagnosis of prostate cancer.- Medical management of patients with prostate cancer.- Conclusions.

Über Autor(innen)

Nicholas James, PhD, is Professor of Clinical Oncology at the Queen Elizabeth Hospital Birmingham. He has a long-standing interest in the communication of information to patients, and founded the CancerHelp UK website in 1994 (www.cancerhelp.org.uk), now one of the largest patient websites in the world and winner of many awards. Professor James was also the chair of the Royal College of Radiologists Clinical Oncology Audit Committee. He has written numerous research papers as well as a large number of contributions to multi-author textbooks, key review articles plus Cancer: A Very Short Introduction a cancer book aimed at the general public. His research is focused on prostate cancer and he is the chief investigator on two current major Phase III trials, TRAPEZE and STAMPEDE, now the largest interventional prostate cancer trial.